10-Q: Exact Sciences Q3 2025: Revenue Up 20%, New Tests Launched

Exact Sciences Corporation reported a 20% year-over-year revenue increase in Q3 2025, driven by strong Cologuard and Oncotype DX test volumes, alongside the launch of new cancer screening and diagnostic products.

Summary

• Total revenue increased 20% year-over-year to $850.7 million for Q3 2025 and 15.8% to $2.37 billion for the nine months ended September 30, 2025.
• Net loss for Q3 2025 was $(19.6) million, an improvement from $(38.2) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $(122.0) million, an improvement from $(164.3) million in the same period last year.
• Cash provided by operating activities for the nine months ended September 30, 2025, was $339.7 million, a significant improvement of $176.3 million year-over-year.
• Launched Cologuard Plus, Oncodetect MRD, and Cancerguard tests, expanding the product portfolio.
• Announced a multi-year productivity plan targeting over $150.0 million in expected annual savings by 2026.
• Entered into a Collaboration and License Agreement with Freenome Holdings, Inc. for blood-based CRC screening tests, including a $75.0 million upfront payment in November 2025 and potential milestones up to $700.0 million.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significantly reduced its net loss, driven by successful product launches and increased adoption of existing tests. Positive operating cash flow and a clear productivity plan indicate improving financial health. However, the company continues to operate at a net loss and faces ongoing intellectual property litigation, which introduces some uncertainty.

Positives

• Total revenue increased 20% year-over-year in Q3 2025 to $850.7 million.
• Screening revenue grew 22.3% in Q3 2025, driven by Cologuard test volume, rescreen rates, care gap programs, and new ordering providers.
• Precision Oncology revenue increased 12.7% in Q3 2025, primarily due to an increased number of completed Oncotype DX breast cancer tests, particularly in Japan.
• Net loss significantly improved to $(19.6) million in Q3 2025 from $(38.2) million in Q3 2024.
• Cash provided by operating activities for the nine months ended September 30, 2025, was $339.7 million, a $176.3 million improvement year-over-year.
• Launched Cologuard Plus, Oncodetect MRD, and Cancerguard tests, expanding the product portfolio.
• Cologuard Plus test reduces false positives by nearly 40% and achieved 95% overall cancer sensitivity in the pivotal BLUE-C study.
• Oncodetect MRD test obtained Medicare reimbursement through the MolDX program effective April 2025 for serial use in patients with stage II, III, and resectable stage IV colorectal cancer.
• Cancerguard test showed 68% sensitivity across six of the deadliest cancers and 97.4% specificity in the multi-center, prospective, case-control ASCEND-2 study.
• Reached a new milestone of 500 unique healthcare organization interface connections with the ExactNexus™ technology platform.
• A multi-year productivity plan targets over $150.0 million in expected annual savings by 2026.
• The U.S. Supreme Court affirmed the ACA mandate for coverage of USPSTF A or B rated services, including Cologuard and Cologuard Plus, ensuring no disruption in coverage.

Negatives

• Still incurring net losses: $(19.6) million in Q3 2025 and $(122.0) million for the nine months ended September 30, 2025.
• Accumulated deficit of approximately $4.62 billion as of September 30, 2025.
• Gross margin decreased slightly for the three and nine months ended September 30, 2025, primarily due to an increase in volume from certain care gap programs.
• General and administrative expenses increased for the three and nine months ended September 30, 2025, primarily due to restructuring and business transformation related costs and an increase in certain incentive-based compensation arrangements.
• Impairment charges of $543 thousand in Q3 2025 and $6.8 million for the nine months ended September 30, 2025, related to certain domestic facilities and corresponding leasehold improvements.
• Interest expense, net, increased to $9.8 million in Q3 2025 from $9.6 million in Q3 2024, and to $29.6 million for the nine months ended September 30, 2025, from $17.4 million in the same period last year.
• The Patent Trial and Appeals Board (PTAB) issued a decision finding all claims of the 781 Patent unpatentable in the ongoing intellectual property litigation with Geneoscopy, Inc.

Risks

• Ability to successfully develop and commercialize new products and services and assess potential market opportunities.
• Ability to successfully and profitably market products and services.
• Acceptance of products and services by patients and healthcare providers.
• Reliance upon certain suppliers.
• Ability to retain and hire key personnel.
• Approval and maintenance of adequate reimbursement rates for products and services within and outside of the U.S.
• Amount and nature of competition for products and services.
• Effects of any judicial, executive or legislative action affecting the company or the healthcare system.
• Government shutdowns and changes in government policies, laws, regulations, and staffing.
• Recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or products and services.
• Ability to obtain and maintain regulatory approvals and comply with applicable regulations.
• Ability to protect and enforce intellectual property, including ongoing litigation with Geneoscopy regarding patent validity, where the PTAB found claims of the 781 Patent unpatentable.
• Success establishing and maintaining collaborative, licensing and supplier arrangements.
• Results of validation studies and clinical trials may differ materially from previous results.
• Ability to manage an international business and expectations regarding international expansion.
• Potential effects of changing macroeconomic conditions and geopolitical conflict.
• Possibility that anticipated benefits from business acquisitions or collaborative/licensing arrangements will not be realized in full or at all or may take longer than expected.
• Possibility that anticipated benefits from restructuring and cost reduction initiatives will not be realized in full or at all or may take longer than expected.
• Outcome of any potential litigation or legal proceedings.
• Ability to raise the capital necessary to support operations or meet payment obligations under indebtedness.
• Disruptions at the FDA and other government agencies caused by government shutdowns, policy changes, funding shortages, or key personnel disruptions could prevent new products from being reviewed or approved in a timely manner.
• Uncertainty regarding future profitability or sustained profitability given historical losses and accumulated deficit.

Future Outlook

Expect continuing revenue growth for Cologuard and Oncotype tests, with additional growth anticipated from recent and upcoming product launches. Research and development expenses are projected to increase as the company enhances current products and invests in its pipeline, including the introduction of a next-generation MRD test leveraging MAESTRO technology in 2026 and the initiation of the FDA registrational SOAR trial for MCED test development. Sales and marketing expenses are expected to increase but decrease as a percentage of revenue over time. General and administrative expenses are forecast to stabilize and decrease due to efficiencies and the multi-year productivity plan, which targets over $150.0 million in annual savings by 2026. The company anticipates that current cash, cash equivalents, marketable securities, and operating cash flows will be sufficient to fund operations for at least the next twelve months.

Management Comments

• Growing total revenue 20% year-over-year while decreasing operating expenses as a percentage of revenue.
• Delivering a record number of orders and shipments in our gap closure program that helps payers close gaps in guideline recommended preventive cancer screening.
• Generating cash provided by operating activities of $339.7 million for the nine months ended September 30, 2025, an improvement of $176.3 million in comparison to the nine months ended September 30, 2024.
• Launching Cancerguard, the first commercially available multi-cancer early detection (MCED) blood test analyzing multiple biomarker classes.
• Expanding the impact of our ExactNexus™ technology platform by reaching a new milestone of 500 unique healthcare organization interface connections.
• Our top priorities for 2025 are to (1) champion our customers and team, (2) elevate our product portfolio, and (3) amplify our impact.
• We estimate there are up to 55 million Americans that are not up to date with their colon cancer screenings.
• We aim to partner with them to implement our Cologuard and Cologuard Plus tests within these programs as a solution for patients who infrequently visit their health care provider.
• We expect that cash, cash equivalents and marketable securities on hand at September 30, 2025, along with cash flows generated through our operations, will be sufficient to fund our current operations for at least the next twelve months based on current operating plans.

Industry Context

Colorectal cancer remains the second leading cause of cancer deaths in the U.S., highlighting the critical need for effective screening solutions like Cologuard. The fixed capacity of screening colonoscopies in the U.S. creates a market opportunity for non-invasive tests, with health systems and payers motivated to increase screening rates due to quality measures like HEDIS and Medicare Stars. The affirmation of the ACA mandate by the U.S. Supreme Court ensures continued coverage for USPSTF A or B rated services, reinforcing the market position of Cologuard and Cologuard Plus. Internationally, breast cancer is a significant health concern in Japan, presenting a growth opportunity for Oncotype DX tests. The company operates within a dynamic macroeconomic environment, facing potential impacts from factors such as inflation, interest rate fluctuations, and government shutdowns, which could affect consumer behavior, medical provider actions, or supplier operations.

Comparison to Industry Standards

• Cologuard test is the first and only FDA-approved sDNA non-invasive colorectal cancer (CRC) screening test.
• Oncotype DX Breast Recurrence Score test is the only test shown to predict both the likelihood of chemotherapy benefit and cancer recurrence in the most common sub-type of early-stage breast cancer, recognized globally as standard of care and included in all major breast cancer treatment guidelines.
• The OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today, with an extensive panel of approximately 20,000 genes and 169 introns.
• Cancerguard is the first commercially available multi-cancer early detection (MCED) blood test analyzing multiple biomarker classes.
• The planned FDA registrational Study of All comeRs (SOAR) trial for MCED test development is expected to be the largest prospective, interventional multi-cancer screening trial ever conducted in the U.S.

Corporate Governance

Legal Proceedings

• Filed suit against Geneoscopy, Inc. in November 2023 in the United States District Court for the District of Delaware, alleging infringement of the 781 Patent and seeking unspecified monetary damages and injunctive relief.
• Amended the complaint in January 2024, alleging Geneoscopy, Inc. made false and misleading statements in marketing its product, in violation of the Lanham Act.
• Filed a second complaint against Geneoscopy, Inc. in May 2024 alleging infringement of U.S. Patent No. 11,970,746, which has been consolidated with the 781 Action.
• Geneoscopy, Inc. filed counterclaims challenging the validity of the patents at issue and alleging breach of contract, misappropriation of trade secrets, unfair competition, and other state and federal law violations.
• The Patent Trial and Appeals Board (PTAB) instituted an inter partes review (IPR) challenging the validity of both the 781 Patent and 746 Patent.
• On July 9, 2025, the PTAB issued a decision finding all claims of the 781 Patent unpatentable; the company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit on September 10, 2025.
• A final decision of the PTAB review of the 746 Patent will be made on or before February 14, 2026.
• On August 21, 2025, the company voluntarily withdrew its motion for preliminary injunction against Geneoscopy, Inc., without prejudice, to preserve the ability to refile after the U.S. Patent and Trademark Office concludes its review of additional asserted patents.
• On August 21, 2025, the Court denied Geneoscopy, Inc.'s motion to stay the district court litigation pending IPR of the 781 and 746 Patents.

Stakeholder Impact

• Shareholders may see potential for increased value from revenue growth, new product launches, and cost savings, but ongoing net losses and intellectual property litigation introduce risk. Bylaw amendments impact shareholder nomination processes and the legal forum for certain disputes.
• Patients will benefit from new and enhanced cancer screening and diagnostic tests (Cologuard Plus, Oncodetect, Cancerguard) for earlier detection and personalized treatment.
• Healthcare Providers will gain access to an expanded portfolio of diagnostic tools and technology platforms (ExactNexus) to improve patient care and screening rates.
• Employees may be impacted by the restructuring of support functions globally as part of the multi-year productivity plan, which includes employee termination benefits.
• Payers will benefit from continued coverage of Cologuard and Cologuard Plus tests, affirmed by the Supreme Court ruling, supporting preventive care. Care gap programs help payers close screening gaps.

Next Steps

• Continue to enhance current products and invest in the pipeline.
• Introduce a next-generation MRD test leveraging MAESTRO technology in 2026.
• Begin recruiting patients for the FDA registrational SOAR trial for MCED test development.
• Complete certain business transformation initiatives by Q4 2026, aiming for over $150.0 million in annual savings.
• Monitor U.S. and global legislative action related to Pillar Two for potential impacts.
• Make a $75.0 million cash payment to Freenome Holdings, Inc. in November 2025.
• Potential additional payments up to $700.0 million to Freenome Holdings, Inc. based on development and regulatory milestones.
• Commit to $20.0 million in joint development costs annually over three years with Freenome Holdings, Inc., beginning on the Antitrust Clearance Date.

Key Dates

Recommendation

Exact Sciences demonstrated robust revenue growth and a notable reduction in net losses, driven by successful new product introductions and increased adoption of its core Cologuard and Oncotype DX tests. The multi-year productivity plan targeting significant annual savings by 2026 provides a clear path towards sustained profitability. The strategic collaboration with Freenome for blood-based CRC screening and the affirmation of ACA coverage for Cologuard are strong long-term catalysts. However, the company continues to incur net losses and carries a substantial accumulated deficit. The ongoing intellectual property litigation with Geneoscopy, particularly the PTAB's finding against the 781 Patent, introduces a material legal risk that could impact future operations and financial performance. Given the balanced outlook of strong operational momentum against persistent losses and legal uncertainties, a 'hold' recommendation is appropriate, advising investors to monitor the execution of the productivity plan, progress towards profitability, and the resolution of the IP disputes.

Keywords

Exact Sciences, EXAS, cancer screening, diagnostic tests, Cologuard, Oncotype DX, Cancerguard, Oncodetect, colorectal cancer, multi-cancer early detection, MRD test, precision oncology, biotechnology, medical devices, SEC filing, 10-Q, financial results, Q3 2025, revenue growth, net loss, operating cash flow, product launch, FDA approval, Medicare reimbursement, intellectual property litigation, Freenome, productivity plan